Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive's Andrew Scott soon after announcing they've received Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US. They've registered Striate+ as the new global brand for the CelGro dental bone and tissue regeneration product and the company will market the procedure in the US under this brand.
Orthocell's Paul Anderson hails FDA approval for dental bone and tissue regeneration product
Quick facts: Orthocell Ltd
Price: 0.525 AUD
Market Cap: $99.12 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE